THREATENED PRETERM LABOR (tPTL)

FLAME LECTURE: 124
BURNS/STELLER 3.16.19
LEARNING OBJECTIVES

- Identify risk factors for preterm labor
- Describe the signs and symptoms of preterm labor

See also:
- Flame 125 – Mgmt of Preterm Labor
- Flame 126 – Adverse Outcomes of PTD
- Flame 127 – Ruling Out ROM
- Flame 129 – Management of PROM
BACKGROUND

PTD EPIDEMIOLOGY & DEFINITIONS

- 400,000 preterm deliveries (PTDs) in U.S. annually (~10% of all deliveries)
- PTD is responsible for 28% of non-chromosomally-related M&M
- PTD is defined as delivery <37 weeks
  - <34 weeks: early preterm birth
  - 34-37 weeks: late preterm birth
BACKGROUND

PTL DEFINITIONS

- Preterm Labor: Contractions + Cervical Change (dilation/effacement) <37 weeks GA
  - Some women will have cervical changes without contractions (cervical insufficiency)
  - Some women will have symptoms w/o cervical change (threatened PTL (tPTL), or just Braxton Hicks contractions)

- 85% of pts admitted for tPTL do not deliver w/in 7 days
  - Most get BMZ for fetal lung maturity
  - Avg price of admission for PTL <34wks (w/o delivery) is $20,300\(^1\)
BACKGROUND

RISK FACTORS FOR PTD

- Previous PTD
  - 1.5-2X more likely to have subsequent PTD
  - Risk becomes progressively higher with increased number of PTDs
  - Likewise, risk decreased the more remote a PTD was OR if there has been a subsequent term delivery
- Short cervix (<2.5cm)
- PROM (prelabor rupture of membranes)
- Multiple gestation
- Tobacco and illicit substance abuse
- Underweight pre-pregnancy BMI
- Short interpregnancy interval
- Chorioamnionitis / UTIs / Bacterial vaginosis
- Mullerian anomalies
HOW DO WE EVAL FOR PTL?

► **Standard clinical assessment (SCA)** includes: history, continuous fetal monitoring (CFM), sterile pelvic exam (SPE), and sterile speculum exam (SSE)

► Lofti 2017 evaluated SCA in 148 women 24-36 6/7 wks
  - tPTL symptoms: contractions, cramping, intermittent lower abdominal pain, back pain, pelvic pressure, vaginal bleeding
  - Exclusions: moderate bleeding, previa, SROM, >3cm dilated, intercourse w/in 24 hours of time of evaluation, <18 yo, multiples

► Prediction of delivery within 7 (& 14 days in parentheses) is BAD (only 10%), however, NPV was good

<table>
<thead>
<tr>
<th>METRIC</th>
<th>SENSITIVITY</th>
<th>SPECIFICITY</th>
<th>PPV</th>
<th>NPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCA</td>
<td>100% (100%)</td>
<td>41% (42%)</td>
<td>10% (14%)</td>
<td>100% (100%)</td>
</tr>
</tbody>
</table>
CAN CERVICAL LENGTH (CL) HELP?

Nikolova 2015:

- SCA + CL performed in 203 singletons between 20 0/7 – 36 6/7 weeks for risk of labor <7 days
- tPTL symptoms: contractions, cramping, intermittent lower abdominal pain, back pain, pelvic pressure, vaginal bleeding
- Exclusions: moderate bleeding, previa, SROM, >3cm dilated, intercourse w/in 24 hours of time of evaluation, <18 yo, multiples
- Prediction of delivery within 7 days with CL <2.5 is BAD (~30%)

<table>
<thead>
<tr>
<th>METRIC</th>
<th>SENSITIVITY</th>
<th>SPECIFICITY</th>
<th>PPV</th>
<th>NPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL &lt;2.5cm</td>
<td>57%</td>
<td>73%</td>
<td>30%</td>
<td>89%</td>
</tr>
</tbody>
</table>

- Interestingly, 100% of patients with CL <1.5 delivered in <7D, and 3% of pts w/ CL >3.5 delivered in <7D; CL between 1.5-3.5 was not helpful
THUS, THE STANDARD OF CARE (SCA +/- CL) HAS NOT BEEN GREAT FOR PREDICTING PTD!

CAN BIOMARKERS HELP?

FETAL FIBRONECTIN (FFN)
fFN HAS BEEN THE RECENT STANDARD

HOW IT WORKS IN PRACTICE

- Used as an aid to assess risk of delivery within 7-14 days between 24 0/7-34 6/7 weeks with tPTL (who have INTACT cervical membranes AND <3cm cervical DILATION)
  - NOT to be used in women >3cm dilated, SROM, cervical cerclage, or bleeding
- In practice, fFN is used for its NPV, not its PPV!
  - If fFN is negative, you can be fairly confident that the patient is unlikely to deliver in the next 7 days (maybe even 14 days)
  - If fFN is positive… then you wish you hadn’t even sent it because it is not helpful in determining risk of PTD
BACKGROUND
WHAT IS fFN?

- It is a protein typically localized in the extracellular matrix of the choriodecidual junction.
- It is unclear exactly how fFN appears in cervico-vaginal secretions.
  - Mechanical stress caused by uterine contractions and cervical change leading to choriodecidual separation?
  - Localized inflammation (from infection) leading to breakdown of the choriodecidual interface?
NEWER BIOMARKERS

PAMG-1 (PARTOSURE)

PHIGFBP-1 (ACTIM PARTUS)
WHAT IS PAMG-1?

- Human placental alpha macroglobulin-1 historically is a protein isolated from amniotic fluid.
- It can also be found in cervico-vaginal discharge (however at several thousand times lower concentration).
- Thus, it was originally extensively used as AmniSure to evaluate for ruptured membranes.
BACKGROUND
WHAT IS phIGFBP-1?

- Also called placental protein 12, it is a protein synthesized in decidualized endometrial cells during pregnancy
- Appears to be regulated by HCG and progesterone
- Has abundant functions during implantation and throughout pregnancy
- Absent in the vagina under normal conditions
148 singletons between 24 0/7 – 36 6/7 weeks were evaluated for risk of labor within 7 and 14 days

Previously hidden from the 1st slide was that PAMG-1 was also collected and clinicians were blinded to its outcome

Results for prediction of delivery <7D (and <14D in parentheses), and PAMG-1 greatly improved PPV, while retaining very high NPV

<table>
<thead>
<tr>
<th>METRIC</th>
<th>SENSITIVITY</th>
<th>SPECIFICITY</th>
<th>PPV</th>
<th>NPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCA</td>
<td>100% (100%)</td>
<td>41% (42%)</td>
<td>10% (14%)</td>
<td>100% (100%)</td>
</tr>
<tr>
<td>PAMG-1</td>
<td>63% (55%)</td>
<td>98% (99%)</td>
<td>71% (86%)</td>
<td>98% (96%)</td>
</tr>
</tbody>
</table>

Conclusion of investigators: 81/132 pts had been admitted for observation 2/2 concern or tPTL by SCA → 8/81 delivered <7D → thus potentially 73/81 of the admissions “may have been prevented with help of PAMG-1”
PAMG-1 COMPARED TO fFN?
BACK TO NIKOLOVA 2015

- 203 singletons between 20 0/7 – 36 6/7 weeks for risk of labor <7D
  - Previously hidden from the slide was that PAMG-were also collected and clinicians were blinded to its outcome

<table>
<thead>
<tr>
<th>METRIC</th>
<th>SENSITIVITY</th>
<th>SPECIFICITY</th>
<th>PPV</th>
<th>NPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL &lt;2.5cm</td>
<td>57%</td>
<td>73%</td>
<td>30%</td>
<td>89%</td>
</tr>
<tr>
<td>PAMG-1</td>
<td>80%</td>
<td>95%</td>
<td>76% (82%)</td>
<td>98% (93%)</td>
</tr>
<tr>
<td>fFN</td>
<td>50%</td>
<td>72%</td>
<td>25% (42%)</td>
<td>91% (82%)</td>
</tr>
</tbody>
</table>

- Results for prediction of delivery <7D (and <14D in parentheses)
- PAMG-1 has better (but not perfect) PPV, and still better NPV
Evaluated SCA + CL + all 3 biomarkers and compared them (after separating pts into three groups by CL) for their ability to predict PTD w/in 7 days

- Low risk (CL >3cm), High risk (CL <1.5cm), Mod. risk (CL 1.5-3cm)
- PAMG-1 was found to be generally better in most aspects
- Below are the statistics for theses markers irrespective of CL

<table>
<thead>
<tr>
<th>METRIC</th>
<th>SENSITIVITY</th>
<th>SPECIFICITY</th>
<th>PPV</th>
<th>NPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>fFN</td>
<td>68%</td>
<td>84%</td>
<td>34%</td>
<td>83%</td>
</tr>
<tr>
<td>PAMG-1</td>
<td>76%</td>
<td>97%</td>
<td>76%</td>
<td>97%</td>
</tr>
<tr>
<td>phIGFBP-1</td>
<td>93%</td>
<td>76%</td>
<td>35%</td>
<td>99%</td>
</tr>
</tbody>
</table>
CONCLUSIONS

- There is no perfect way to rule out PTL, thus extended observation of patients with concern for PTL remains important for decreasing fetal morbidity/mortality.
- A biomarker such as PAMG-1 retains strong NPV, while having the strongest predictive accuracy and may assist with evaluation of tPTL.
  - Further, in Melchor 2018, the positivity rate for PAMG-1 in pts with tPTL was 7.9% (compared to 23-30% for the other two markers).
    - Thus, a lower overall positivity rate + a higher PPV may reduce the rate of unnecessary hospitalization and/or transfer for tPTL.
- Remember that blood, lubricating jelly, betadine, and antibiotic creams can interfere with biomarkers.
- Generic soaps, creams, semen, urine, vaginitis will not interfere.
REFERENCES

2. ACOG PB 171: Management of Preterm Labor (2016)